Wellington Management Group
KROS icon

Wellington Management Group’s Keros Therapeutics KROS Stock Holding History

Wellington Management Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,033
Closed -$222K – 1999
2024
Q4 		$222K Sell
14,033
-916
-6% -$47.6K ﹤0.01% 1898
2024
Q3 		$868K Buy
+14,949
New +$738K ﹤0.01% 1739
2023
Q2 		– Sell
-16,654
Closed -$711K – 1914
2023
Q1 		$711K Sell
16,654
-1,035
-6% -$52.3K ﹤0.01% 1772
2022
Q4 		$849K Sell
17,689
-1,080
-6% -$50.4K ﹤0.01% 1674
2022
Q3 		$706K Sell
18,769
-215
-1% -$7.45K ﹤0.01% 1718
2022
Q2 		$524K Hold
18,984
– – ﹤0.01% 1824
2022
Q1 		$1.03M Buy
18,984
+227
+1% +$11.7K ﹤0.01% 1730
2021
Q4 		$1.1M Buy
+18,757
New +$935K ﹤0.01% 1783

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group's KROS Position: Q1 2025 in Review

Wellington Management Group sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 14,033 shares — an estimated $222K sold.

Wellington Management Group first reported a position in KROS in Q4 2021 and held it in 8 quarters. The position peaked at $1.1M in Q4 2021. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Wellington Management Group reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Wellington Management Group sold 14,033 Keros Therapeutics shares in Q1 2025, an estimated $222K.
  • Wellington Management Group first reported a position in Keros Therapeutics in Q4 2021 and held it in 8 quarters.
  • Wellington Management Group's Keros Therapeutics position peaked at $1.1M in Q4 2021.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Wellington Management Group's 13F filing for Q1 2025, filed 13 May 2025.